CA-DEXCOM-INC
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
Focused on clinical outcomes of CGM use in broader and more diverse populations and new data from Dexcom’s next-generation G7 CGM, these two studies mark a pivotal moment in diabetes care innovation at one of the world’s leading industry conferences.
MOBILE Study
The MOBILE study
, published in the Journal of the American Medical Association
, is the first of its kind to find that people with Type 2 diabetes who use basal, or background, insulin, benefited from the use of CGM. With the publication of the MOBILE data, Dexcom has now demonstrated significant outcomes driven by its CGM technology in randomized controlled trials across the full spectrum of insulin use in people with diabetes.
Key clinical benefits of Dexcom CGM use in this population included:
- Increased time in range
- Significant A1c reduction
- More patients reaching A1c goals
- A profound decrease in hyperglycemia
The randomized clinical trial led by HealthPartners Institute’s International Diabetes Center and coordinated by The Jaeb Center for Health Research in Tampa, Fla. affirms Dexcom’s belief in the power of CGM for all people with diabetes regardless of Type.
“The clinical benefits of Dexcom CGM were seen across all patient demographics regardless of age, education, numeracy or socioeconomic status,” said David Price, MD, vice president of medical affairs at Dexcom. “The MOBILE study design also affirms our ability to meet the needs of the diverse communities we serve.”
MOBILE Study Findings
- The group of patients using Dexcom CGM spent an average of 3.8 hours more each day within the optimal range of blood glucose levels (70-180 mg/dL), 3.6 hours less each day in the very high glucose range (>250 mg/dL), and with a reduction in CGM measured hypoglycemia in the CGM group compared to the finger-stick glucose monitoring group
- 63% of patients using CGM to guide therapy adjustments had an HbA1c less than 8% compared to only 39% of patients using finger-stick glucose reading
- The group using CGM to guide therapy and lifestyle adjustments also had significantly lower HbA1c levels (9.1 to 8.0%) than the group of patients using traditional finger-stick glucose monitoring (9.0 to 8.4%); this was an adjusted difference in mean change in HbA1c of −0.4%, 95% CI –0.8% to −0.1%, P=0.02
- Adherence and satisfaction were also high among the CGM group
MOBILE Study Design
- Eight-month study of 175 ethnically and socioeconomically diverse adults (including >50% people of color) across 15 clinical sites
- Type 2 diabetes age 30 years or older who were receiving diabetes care from a primary care provider trying to manage their diabetes using basal or background insulin, but not using faster-acting insulin at meals
- Two-thirds of the trial participants were assigned to use Dexcom CGM and encouraged to use Dexcom’s CLARITY, Share and Follow software applications; the remaining one third of the trial patients were assigned to use the traditional blood glucose meter
Dexcom G7 Data
Dexcom also presented new data on its next generation interoperable CGM, Dexcom G7, drawn from clinical trials supporting the company’s efforts toward a CE Mark submission and US pre-pivotal work. The data represents the latest G7 technology, demonstrating the consistent performance of the sensor across the spectrum of glucose readings and duration of wear.
G7 Results (approximately 360 sensor sessions)
- An overall mean absolute relative difference (MARD) of 8.7%
- 93.8 percent %20/20
- 99% of sensor readings were clinically accurate and safe for treatment decisions
Expected Dexcom G7 Features and Benefits
- 60% smaller wearable than G6
- Smaller all-in-one sensor applicator and transmitter
- 30-minute warm-up
- Interoperability with insulin delivery devices
- Maintaining world class customer experience
- Continued best-in-class accuracy
“Initial clinical data has only strengthened our conviction that Dexcom G7 will build upon the high accuracy standard already established by our G6 CGM system,” said Jake Leach, executive vice president and chief technology officer at Dexcom. “The G7 is a completely redesigned CGM; our users will get a whole suite of new features that we believe will enhance the customer experience that has become synonymous with Dexcom.”
In addition to the MOBILE study and G7 data, many other presentations and posters from ATTD reinforced the benefits of Dexcom CGM for intensive insulin management, as well as its use in inpatient settings and during pregnancy.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005717/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Germany’s Largest Public Insurer Versicherungskammer Selects Clearwater Analytics for Scalable Investment Operations2.7.2025 09:00:00 CEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Versicherungskammer Group has selected Clearwater Analytics’ platform to power their middle, back office and risk functions. This decision is based on a comprehensive operating model review that began in 2024, followed by a structured selection process to identify a strategic partner. The rigorous assessment underscored the need for change, as market developments and demographic shifts demanded more agility, transparency, and efficiency. By adopting Clearwater’s modern, cloud-based platform, Versicherungskammer will gain real-time, advanced data analytics to strengthen investment decision-making and drive improved performance. This will allow Versicherungskammer to focus on its core competencies in capital investment in the future. “Partnering with Clearwater marks an important shift in our investment operations strategy and is central to our goal of future-proo
Ant International Launches Alipay+ Voyager, a Built-in End-to-End AI Travel Companion for Digital Wallet and Super App Users2.7.2025 08:12:00 CEST | Press release
Alipay+ Voyager converts Alipay+'s agentic travel AI solutions into one multi-task interface for e-wallet and super app usersOTA and travel merchant partners such as Agoda, Fliggy and Trip.com offer seamless, end-to-end traveller experience through Alipay+'s global partner apps, from trip planning, trip booking to product and service discoveryAlipay+ plans to further deepen and expand its AI offerings for fintechs and super apps as a global wallet gateway for connectivity and growth. With launch partners including Agoda, Fliggy and Trip.com, Ant International introduces Alipay+ Voyager, an AI travel companion integrated into digital wallets for the travel industry to simplify and enhance travel experiences for global consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701160496/en/ A sample user interface of Alipay+ Voyager, which users can access via digital wallets Alipay+ Voyager combines Ant International's agen
Access Advance Welcomes Global Technology Leaders as Licensees and Licensors to New Video Distribution Patent Pool2.7.2025 02:00:00 CEST | Press release
Access Advance LLC ("Advance") today announced the inaugural roster of licensees and licensors for its Video Distribution Patent ("VDP") Pool, marking a significant milestone in the program's rapid market adoption since its January announcement. The participation of major global companies heavily involved in video codec technology demonstrates strong industry support for the comprehensive licensing solution covering HEVC, VVC, VP9, and AV1 codecs. The VDP Pool has successfully attracted a group of licensees/licensors including ByteDance, Kuaishou, NTT Docomo, and Tencent. This represents the beginning of what Access Advance expects to be widespread adoption among content streaming providers seeking simplified codec licensing. The licensees’ participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. "We're pleased to welcome ByteDance, Kuaishou, NTT Docomo and Tencent as our
Intralot S.A. to Acquire Bally’s International Interactive Business in a Transaction that Creates a Global Gaming Technology and Services Company in Lottery and Digital Online Gaming Markets1.7.2025 21:10:00 CEST | Press release
Intralot S.A. to Remain Listed on the Athens Stock ExchangeTransaction Enterprise Value of €2.7 Billion Intralot S.A. (ATSE: INLOT) (“Intralot”) and Bally’s Corporation (NYSE: BALY) (“Bally’s”) today announced that their respective Boards of Directors approved their entry into a definitive transaction agreement (“Transaction Agreement”) pursuant to which Intralot will acquire Bally’s International Interactive business (the “International Interactive Business”) in a cash-and-shares transaction that values the International Interactive Business at an enterprise value of €2.7 billion (the “Transaction”). The consideration for the acquisition of the International Interactive Business will comprise a combination of cash paid by Intralot and newly issued shares delivered by Intralot to Bally’s, as more specifically detailed below. As part of the Transaction, Intralot expects to refinance part of its existing debt facilities and Bally’s also expects to repay secured debt from the cash proceed
Valeo Foods Group Acquires Melegatti Cakes Expanding the Italian Bakery Portfolio1.7.2025 18:21:00 CEST | Press release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the assets of an Italian panettone, pandoro and croissant producer, Melegatti 1894 S.p.A.This acquisition is another step forward in Valeo Foods Groups’ strategy to expand its baked sweet treats portfolio, and reinforces Valeo’s commitment to bringing authentic Italian confections and established regional brands to a wider international audience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702677156/en/ Melegatti Founded in 1894 in Verona, Melegatti has a strong reputation for artisanal cakes - particularly pandoro, panettone and filled croissants - traditional recipes, and a rich Italian heritage, Melegatti has a proud legacy founded on family values, craftsmanship, and a passion for quality. “We are excited to welcome Melegatti into the Valeo Foods Group,” said Ronald Kers, Group CEO. “This acquisition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom